Bladder Cancer Trial, Recruiting NCT05453682 Sponsor: Samsung Medical Center Condition: Bladder Cancer
Back to Bladder Cancer

Bladder Cancer Trial, Recruiting

NCT05453682
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with bladder cancer confirmed by a tissue sample (biopsy)
  • People whose cancer has grown into the muscle wall of the bladder (a stage known as pT2 or higher)
  • People whose scans (CT or MRI) show no cancer spread to the lymph nodes in the pelvis
  • People who wish to keep their bladder rather than have it removed as part of their treatment
  • People aged 20 years or older
  • People who are generally well and able to carry out daily activities, based on a standard health assessment done within one week before joining the study
  • People who have signed an informed consent form, either themselves or through a guardian
  • People whose blood test results show their body can handle receiving chemotherapy and radiation therapy together

Who may not be able to join:

  • People who have previously had radiation therapy to the pelvic area
  • People who are pregnant or currently breastfeeding
  • People whose cancer has spread to other parts of the body beyond the pelvis
  • People whose bladder cancer is so widespread that doctors consider it too difficult to safely preserve the bladder
  • People who have had another type of cancer within the last 5 years, unless it was thyroid cancer, a common type of skin cancer (non-melanoma), a very early-stage prostate cancer (T1a), or early cervical cancer confined to the surface layer
  • People who have a serious untreated illness at the time of the study
  • People with connective tissue diseases (such as lupus or scleroderma) that may make radiation treatment risky (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 82-10-9933-2616

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
14 May 2021
Est. completion
31 December 2026

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

bladder preservation disease-free survival rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov